BRIEF:
Small Pharma, is an innovative neuropharma company exploring the use of psychedelics for ground-breaking treatment of depression. When they were granted the world’s first licence for clinical trials of their DMT molecule construct, we were tasked with raising awareness of the company.
SOLUTION:
In order to reach the diverse range of stakeholder audiences which included health professionals, therapists, investors and of course potential end-users, our press-outreach was individually tailored and targeted, carefully balancing serious messaging with the sensationalism and speculation around the use of DMT medically.
RESULTS:
The result was over 20 articles in a broad spectrum of national, lifestyle, and financial titles plus significant features in VICE, The Financial Times and The Guardian
